Dominant drug targets suppress the emergence of antiviral resistance

  1. Elizabeth J Tanner
  2. Hong-mei Liu
  3. M Steven Oberste
  4. Mark Pallansch
  5. Marc S Collett
  6. Karla Kirkegaard  Is a corresponding author
  1. Stanford University School of Medicine, United States
  2. Centers for Disease Control and Prevention, United States
  3. ViroDefense, Inc., United States

Abstract

The emergence of drug resistance can defeat the successful treatment of pathogens that display high mutation rates, as exemplified by RNA viruses. Here we detail a new paradigm in which a single compound directed against a 'dominant drug target' suppresses the emergence of naturally occurring drug-resistant variants in mice and cultured cells. All new drug-resistant viruses arise during intracellular replication and initially express their phenotypes in the presence of drug-susceptible genomes. For the targets of most anti-viral compounds, the presence of these drug-susceptible viral genomes does not prevent the selection of drug resistance. Here we show that, for an inhibitor of the function of oligomeric capsid proteins of poliovirus, the expression of drug-susceptible genomes causes chimeric oligomers to form, thus rendering the drug-susceptible genomes dominant. The use of dominant drug targets should suppress drug resistance whenever multiple genomes arise in the same cell and express products in a common milieu.

Article and author information

Author details

  1. Elizabeth J Tanner

    Stanford University School of Medicine, Stanford, United States
    Competing interests
    No competing interests declared.
  2. Hong-mei Liu

    Centers for Disease Control and Prevention, Atlanta, United States
    Competing interests
    No competing interests declared.
  3. M Steven Oberste

    Centers for Disease Control and Prevention, Atlanta, United States
    Competing interests
    No competing interests declared.
  4. Mark Pallansch

    Centers for Disease Control and Prevention, Atlanta, United States
    Competing interests
    No competing interests declared.
  5. Marc S Collett

    ViroDefense, Inc., Rockville, United States
    Competing interests
    Marc S Collett, President of ViroDefense, Inc., the sponsoring firm for development of V-073.
  6. Karla Kirkegaard

    Stanford University School of Medicine, Stanford, United States
    For correspondence
    karlak@stanford.edu
    Competing interests
    No competing interests declared.

Reviewing Editor

  1. Wenhui Li, National Institute of Biological Sciences, Beijing, China

Ethics

Animal experimentation: Mice used in these studies were bred and housed under specific pathogen-free conditions at the Stanford University animal care facility, which is accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care, Int. All experiments were approved by Stanford's Institutional Animal Care and Use Committee (Administrative Panel of Laboratory Animal Care). The Assurance number for this panel is A3213-01; the Protocol ID is 9296. For survival studies, mice were euthanized when moribund or upon initial signs of paresis/paralysis.

Version history

  1. Received: June 28, 2014
  2. Accepted: November 1, 2014
  3. Accepted Manuscript published: November 3, 2014 (version 1)
  4. Version of Record published: December 8, 2014 (version 2)

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 2,230
    views
  • 259
    downloads
  • 37
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Elizabeth J Tanner
  2. Hong-mei Liu
  3. M Steven Oberste
  4. Mark Pallansch
  5. Marc S Collett
  6. Karla Kirkegaard
(2014)
Dominant drug targets suppress the emergence of antiviral resistance
eLife 3:e03830.
https://doi.org/10.7554/eLife.03830

Share this article

https://doi.org/10.7554/eLife.03830

Further reading

    1. Chromosomes and Gene Expression
    Joshua D Eaton, Jessica Board ... Steven West
    Short Report

    RNA polymerase II (RNAPII) transcription initiates bidirectionally at many human protein-coding genes. Sense transcription usually dominates and leads to messenger RNA production, whereas antisense transcription rapidly terminates. The basis for this directionality is not fully understood. Here, we show that sense transcriptional initiation is more efficient than in the antisense direction, which establishes initial promoter directionality. After transcription begins, the opposing functions of the endonucleolytic subunit of Integrator, INTS11, and cyclin-dependent kinase 9 (CDK9) maintain directionality. Specifically, INTS11 terminates antisense transcription, whereas sense transcription is protected from INTS11-dependent attenuation by CDK9 activity. Strikingly, INTS11 attenuates transcription in both directions upon CDK9 inhibition, and the engineered recruitment of CDK9 desensitises transcription to INTS11. Therefore, the preferential initiation of sense transcription and the opposing activities of CDK9 and INTS11 explain mammalian promoter directionality.

    1. Chromosomes and Gene Expression
    Chaitra Shree Udugere Shivakumara Swamy, Thomas C Boothby
    Insight

    Tiny animals known as tardigrades use a combination of DNA repair machinery and a novel protein to mend their genome after intense ionizing radiation.